Biology of glial cell line-derived neurotrophic factor (GDNF): Implications for the use of GDNF to treat Parkinson's disease

Neurodegeneration

Volumn 5, Issue 3, 1996, Pages 197-205

  Lapchak, Paul A ^a   Miller, Paul J ^a   Jiao, Shoushu ^a   Araujo, Dalia M ^a   Hilt, Dana ^a   Collins, Frank ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; IODINE 123; METHAMPHETAMINE; NEUROTOXIN; NEUROTROPHIC FACTOR; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BEHAVIOR; CELL DEATH; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG DISTRIBUTION; GLIA CELL; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MESENCEPHALON; MORPHOLOGY; NERVE REGENERATION; NEUROCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; REVIEW; RHESUS MONKEY;

EID: 0030248826     PISSN: 10558330     EISSN: None     Source Type: Journal    
DOI: 10.1006/neur.1996.0027     Document Type: Review

References (39)

1. Blum M, Weickert CS (1995) GDNF mRNA expression in normal postnatal development, aging and in weaver mutant mice. Neurobiol Aging 16:925-929
2. Bowenkamp KE, Hoffman AF, Gerhardt GA, Henry MA, Biddle PT, Hoffer BJ, Granholm ACE (1995) Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J Comp Neurol 355:479-489
3. Bowenkamp KE, Lapchak PA, Hoffer BJ, Pickford PC (1996a) Glial Cell Line-Derived Neurotrophic Factor reverses motor impairment in aged rats. Neurosci Lett 211:81-84
4. Bowenkamp KE, David D, Lapchak PA, Henry MA, Granholm AC, Hoffer BJ, Mahalik TJ (1996b) 6-hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. Exp Brain Res (in press)
5. Cass WA, Dugan MT (1996) GDNF protects against methamphetamine-induced reductions in striatal DA release and content in rats. ASNT P58
6. Gash DM, Zhang Z, Cass WA, Ovadia A, Simmerman L, Russell D, Martin D, Collins FC, Hoffer BJ, Gerhardt GA (1995) Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J Comp Neurol 363:345-358.
7. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins FC, Hoffer BJ, Gerhardt GA (1996) Functional recovery in GDNF-treated Parkinsonian monkeys. Nature 380:252-255
8. Gillard ER, Dang DQ, Stanley BG (1993) Evidence that neuropeptide Y and DA in the perifornical hypothalamus interact antagonistically in the control of food intake. Brain Res 628:128-136
9. Hebert MA, van Horne CG, Hoffer BJ, Gerhardt GA (1995) Glial cell line-derived neurotrophic factor augments K+ overflow of dopamine in the striatum. Soc Neurosci 21:225.5
10. Hoffer BJ, Hoffman A, Bowenkamp K (1994) Glial cell derived neurotrophic factor reversed toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 182:107-111
11. Hou JGG, Lin LFH, Mytilineou C (1996) Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. J Neurochem 66:74-82
12. Hudson J, Granholm AC, Gerhardt GA, Henry MA, Hoffman A, Biddle P, Leela NS, Mackerlova L, Lile JD, Collins F, Hoffer BJ (1995) Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res Bull 36:425-432
13. Kalivas PW, Stewart J (1991) Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Rev 16:223-244
14. Kearns CM, Gash DM (1995) GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 672:101-111
15. Langston JW, Forno LS, Rebert CS, Irwin I (1984) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 292:390-394
16. 125I-GDNF in the rat and primate CNS following an icv injection: correlation with the behavioral and pharmacological activities of icv administered GDNF in Parkinson's disease models. ASNT P52
17. Lapchak PA, Jiao S, Miller PJ, Williams LR, Cummins V, Inouye G, Matheson CR, Yan Q (1996b) Pharmacological characterization of glial cell line-derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule for treating neurodegenerative diseases. Cell Tissue Res (in press)
18. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, Jones T, Marsden D, Franchowiak RSJ (1993) The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteers and in patients with Parkinson's disease. Arch Neurol 47:1290-1298
19. Lin L-F, Doherty DH, Lile JD, Bektesh S, Collins F (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132
20. 3H]GBR 12935 binding to DA uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy. Fur J Pharmacol 156:331-340
21. Marsden CD, Parkes JD, Quinn N (1982) Fluctuations of disability in Parkinson's Disease-Clinical aspects. In: Marsden CD and Fahn S eds. Movement Disorders. London, Butterworths Scientific, pp 96-122
22. Martin D, Miller G, Fischer N, Dix D, Cullen T (1996) Glial cell-line derived neurotrophic factor: the lateral cerebral ventricle is an effective site of administration for stimulation of the nigrostriatal system. Eur J Neurosci 8:1249-1255
23. Mount HTJ, Dean DO, Alberch J, Dreyfus CF, Black IB (1995) GDNF promotes the survival and morphologic differentiation of Purkinje cells. PNAS 92:9092-9096
24. Opacka-Juffry J, Ashworth S, Hume SP, Martin D, Brooks DJ, Blunt SB (1995) GDNF protects against 6-OHDA nigrostriatal lesions: in vivo study with microdialysis and PET. NeuroReport 7:348-352
25. Pare D, Curro'Dossi R, Steriade M (1990) Neuronal basis of the parkinsonian resting tremor: a hypothesis and its implications for treatment. Neuroscience 35:217-226
26. Penney JB, Young AB (1992) Movement Disorders. In: Johnston MV, MacDonald RI, Young AB (eds.) Principles of Drug Therapy in Neurology. Philadelphia, F.A. Davis
27. Sauer H, Rosenblad C, Bjorklund A (1995) Glial cell line-derived neurotrophic factor but not transforming growth factor B3 prevents delayed degeneration of nigral neurons following striatal 6-hydroxydopamine lesions. PNAS 92:8935-8939
28. Scharr DG, Sieber BA, Dreyfus CF, Black I (1993) Regional and cell-specific expression of GDNF in rat brain. Exp Neurol 124:368-371
29. Shults CW, Shin C, Ernesto C, and Martin D (1995) Effects of intrastriatal injections of glial cell line-derived neurotrophic factor (GDNF) in rats. Soc Neurosci 21:225.16
30. Smith RD, Zhang Z, Kurlan R, McDermott M, Gash DM (1993) Developing a stable bilateral model of Parkinsonism in rhesus monkey. Neuroscience 52:7-16
31. Springer JE, Seeburger JL, He J, Gabrea A, Blankenhorn EP, Bergman LW (1995) cDNA sequence and differential mRNA regulation of two forms of glial cell line-derived neurotrophic factor in schwann cells and rat skeletal muscle. Exp Neurol 131:47-52
32. Stromberg I, Bjorklund L, Johansson M, Tomac A, Collins F, Olson L, Hoffer BJ, Humpel C (1993) Glial cell line-derived neurotrophic factors is expressed in the developing but not adult striatum and stimulates developing DA neurons in vivo. Exp Neurol 124:401-412
33. Suter-Crazzolara C, Unsicker K (1994) GDNF is expressed in two forms in many tissues outside the CNS. Neuroreport 5:2486-2488
34. Tetrud JW, Langston JW, Garbe PL, Ruttenberger AJ (1989) Mild parkinsonism in persons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurol 39:1483-1487
35. Tomac A, Widenfalk J, Lin LFH, Kohno T, Ebendal T, Hoffer BJ, Olson L (1995a) Retrograde axonal transport of GDNF in the adult nigrostriatal system suggests a trophic role in the adult. PNAS 92:8274-8278
36. Tomac A, Lindqvist E, Lin LFH, Ogren SO, Young D, Hoffer BJ, Olson L (1995b) Protection and repair of nigrostriatal dopaminergic neurons by GDNF in vivo. Nature 373:335-339
37. Torack RM, Morris JC (1992) Tyrosine hydroxylase-like (TH) immunoreactivity in Parkinson's disease and Alzheimer's disease. J Neuroal Transm 4:165-171
38. Trupp M, Ryden M, Jornvall H, Funakoshi H, Timmusk T, Arenas E, Ibanez CF (1995) Peripheral expression and biological activities of GDNF, a new neurotrophic factor for avian and mammalian peripheral neurons. J Cell Biol 130:137-148
39. Vingerhoes FJ, Snow BJ, Tetrud JW, Langston JW, Schulzer M, Calne B (1994) Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol 36:765-770